Exploring the Therapeutic Potential of 5-Fluorouracil-Loaded Calcium Carbonate Nanoparticles Combined with Natural Compound Thymoquinone for Colon Cancer Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Aug 29

PMID 39204357

Authors

Xi Deng

Zhongming Yang

Kim Wei Chan

Md Zuki Abu Bakar

Affiliations

Soon will be listed here.

Abstract

Given the need for novel and effective therapies for colon cancer, this study aimed to investigate the effects of 5-fluorouracil-loaded calcium carbonate nanoparticles (5FU-CaCOnp) combined with thymoquinone (TQ) against colon cancer. A shaking incubator and a high-speed homogenizer were used to prepare the optimal 5FU-CaCOnp, with characterizations of physicochemical properties, in vitro drug release profile, and biocompatibility. In vitro experiments and molecular docking were employed to evaluate the therapeutic potential of the combination for colon cancer treatment. Study results revealed that 5FU-CaCOnp with a size of approximately 130 nm was synthesized using the high-speed homogenizer. Its favorable biocompatibility, pH sensitivity, and sustained release properties facilitated reduced toxic side effects of 5-FU on NIH3T3 normal cells and enhanced inhibitory effects on CT26 colon cancer cells. The combination of 5FU-CaCOnp (1.875 μM) and TQ (30 μM) showed significantly superior anti-colon cancer effects to 5FU-CaCOnp alone in terms of cell proliferation and migration inhibition, cell apoptosis induction, and spheroid growth suppression in CT26 cells ( < 0.05), with strong interactions between the drugs and targets (E-cadherin, Bcl-2, PCNA, and MMP-2). These results provide evidence for 5FU-CaCOnp as a novel regimen against colon cancer. Combining 5FU-CaCOnp and TQ may offer a new perspective for colon cancer therapy.

Citing Articles

5-Fluorouracil in Combination with Calcium Carbonate Nanoparticles Loaded with Antioxidant Thymoquinone against Colon Cancer: Synergistically Therapeutic Potential and Underlying Molecular Mechanism.

Deng X, Yang Z, Chan K, Ismail N, Bakar M Antioxidants (Basel). 2024; 13(9).

PMID: 39334689 PMC: 11429434. DOI: 10.3390/antiox13091030.

Unveiling Drimenol: A Phytochemical with Multifaceted Bioactivities.

Yang Z, Chan K, Bakar M, Deng X Plants (Basel). 2024; 13(17).

PMID: 39273976 PMC: 11397239. DOI: 10.3390/plants13172492.

References

Senapati S, Mahanta A, Kumar S, Maiti P . Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018; 3:7. PMC: 5854578. DOI: 10.1038/s41392-017-0004-3. View

Vergaro V, Pisano I, Grisorio R, Baldassarre F, Mallamaci R, Santoro A . CaCO as an Environmentally Friendly Renewable Material for Drug Delivery Systems: Uptake of HSA-CaCO Nanocrystals Conjugates in Cancer Cell Lines. Materials (Basel). 2019; 12(9). PMC: 6539763. DOI: 10.3390/ma12091481. View

Xie X, Li Y, Lian S, Lu Y, Jia L . Cancer metastasis chemoprevention prevents circulating tumour cells from germination. Signal Transduct Target Ther. 2022; 7(1):341. PMC: 9526788. DOI: 10.1038/s41392-022-01174-w. View

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A . Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022; 72(4):372-401. DOI: 10.3322/caac.21728. View

Borrego-Sanchez A, Sanchez-Espejo R, Albertini B, Passerini N, Cerezo P, Viseras C . Ground Calcium Carbonate as a Low Cost and Biosafety Excipient for Solubility and Dissolution Improvement of Praziquantel. Pharmaceutics. 2019; 11(10). PMC: 6835254. DOI: 10.3390/pharmaceutics11100533. View

Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V . 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2019; 206:107447. DOI: 10.1016/j.pharmthera.2019.107447. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Shen S, Wu Y, Liu Y, Wu D . High drug-loading nanomedicines: progress, current status, and prospects. Int J Nanomedicine. 2017; 12:4085-4109. PMC: 5459982. DOI: 10.2147/IJN.S132780. View

Kensara O, El-Shemi A, Mohamed A, Refaat B, Idris S, Ahmad J . Thymoquinone subdues tumor growth and potentiates the chemopreventive effect of 5-fluorouracil on the early stages of colorectal carcinogenesis in rats. Drug Des Devel Ther. 2016; 10:2239-53. PMC: 4946859. DOI: 10.2147/DDDT.S109721. View

10.

Na T, Schecterson L, Mendonsa A, Gumbiner B . The functional activity of E-cadherin controls tumor cell metastasis at multiple steps. Proc Natl Acad Sci U S A. 2020; 117(11):5931-5937. PMC: 7084067. DOI: 10.1073/pnas.1918167117. View

11.

Pan G, Jia T, Huang Q, Qiu Y, Xu J, Yin P . Mesoporous silica nanoparticles (MSNs)-based organic/inorganic hybrid nanocarriers loading 5-Fluorouracil for the treatment of colon cancer with improved anticancer efficacy. Colloids Surf B Biointerfaces. 2017; 159:375-385. DOI: 10.1016/j.colsurfb.2017.08.013. View

12.

Rajabi S, Ramazani A, Hamidi M, Naji T . Artemia salina as a model organism in toxicity assessment of nanoparticles. Daru. 2015; 23:20. PMC: 4344789. DOI: 10.1186/s40199-015-0105-x. View

13.

Rejhova A, Opattova A, cumova A, Sliva D, Vodicka P . Natural compounds and combination therapy in colorectal cancer treatment. Eur J Med Chem. 2018; 144:582-594. DOI: 10.1016/j.ejmech.2017.12.039. View

14.

Di J, Gao X, Du Y, Zhang H, Gao J, Zheng A . Size, shape, charge and "stealthy" surface: Carrier properties affect the drug circulation time . Asian J Pharm Sci. 2021; 16(4):444-458. PMC: 8520042. DOI: 10.1016/j.ajps.2020.07.005. View

15.

Wahab S, Alshahrani M, Ahmad M, Abbas H . Current trends and future perspectives of nanomedicine for the management of colon cancer. Eur J Pharmacol. 2021; 910:174464. DOI: 10.1016/j.ejphar.2021.174464. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Kumari S, Kondapi A . Lactoferrin nanoparticle mediated targeted delivery of 5-fluorouracil for enhanced therapeutic efficacy. Int J Biol Macromol. 2016; 95:232-237. DOI: 10.1016/j.ijbiomac.2016.10.110. View

18.

Lemech C, Kichenadasse G, Marschner J, Alevizopoulos K, Otterlei M, Millward M . ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study. Oncogene. 2022; 42(7):541-544. PMC: 9918429. DOI: 10.1038/s41388-022-02582-6. View

19.

Blanco E, Shen H, Ferrari M . Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015; 33(9):941-51. PMC: 4978509. DOI: 10.1038/nbt.3330. View

20.

Chen M, Lee N, Hsu H, Ho T, Tu C, Chen R . Inhibition of NF-κB and metastasis in irinotecan (CPT-11)-resistant LoVo colon cancer cells by thymoquinone via JNK and p38. Environ Toxicol. 2016; 32(2):669-678. DOI: 10.1002/tox.22268. View